Novo Nordisk warns consumers about counterfeit versions of Ozempic in US
1. Novo Nordisk identifies counterfeit Ozempic drugs in U.S. supply chain. 2. The counterfeit issue poses risks to brand reputation and patient safety.
1. Novo Nordisk identifies counterfeit Ozempic drugs in U.S. supply chain. 2. The counterfeit issue poses risks to brand reputation and patient safety.
Counterfeit drugs can erode consumer trust and negatively impact sales. Historical examples include decreased stock prices of companies facing similar drug authenticity issues.
The counterfeit discovery could lead to regulatory scrutiny and affect brand reputation, influencing investor confidence.
Immediate concerns over counterfeit products may affect sales and stock performance quickly. Past instances of drug counterfeiting have shown rapid stock reactions.